ISRCTN13752095 · RECRUITING
Shantou Amsterdam study on blood pressure reduction and dementia prevention
This study compares two common blood pressure medicines, ARBs and ACE inhibitors, in adults 65 to 80 with untreated high blood pressure. Researchers will track whether memory and thinking decline, or dementia develops, over five years. Both are existing, approved drugs. No phase is listed, so it is a comparison of standard care options, not a new drug test.
Eligibility criteria
Inclusion Criteria: 1. Individuals aged 65–80 years 2. Not currently on AHM 3. Willing to receive regular (ATC-listed) antihypertensive treatment 4. Current mean SBP ≥140 and/or DBP ≥90 mmHg 5. Who are either: 5.1. Newly diagnosed with primary hypertension 5.2. Previously diagnosed but never treated; or 5.3. Previously treated but stopped AHM >3 years before baseline Exclusion Criteria: 1. Current use of AHM 2. Dementia or relevant cognitive decline (defined as MMSE < 24 points; or < 21 points for ISCED level 1) 3. Contra-indications to use of an ARB or an ACEi
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-07-20
Source: ISRCTN registry, record ISRCTN13752095, retrieved 2026-10-27. Registry text licensed CC BY 4.0.